Press release
Parkinson's Disease-Related Dementia (PDD) Market to Reach USD 7.9 Billion by 2034
Parkinson's Disease-Related Dementia
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71917
Up to 75% of PD patients eventually develop dementia, making PDD a significant public health challenge. The market is shaped by rising aging populations, drug innovations, and improved diagnostic tools, alongside non-drug interventions and caregiver-support models.
Market Overview
• Market Size (2024): USD 4.3 billion
• Forecast (2034): USD 7.9 billion
• CAGR (2025-2034): 6.2%
Growth is fueled by rising PD prevalence, better recognition of cognitive decline, and drug pipeline development targeting alpha-synuclein and neurotransmitter systems.
Key Highlights:
• PDD affects an estimated 5-8 million people globally.
• Cholinesterase inhibitors (rivastigmine, donepezil) remain primary symptomatic treatments.
• Digital cognitive testing and biomarker research are improving early diagnosis.
• Caregiver burden and healthcare costs remain critical challenges.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Cholinesterase Inhibitors (Rivastigmine - FDA approved for PDD, Donepezil)
o NMDA Receptor Antagonists (Memantine - off-label)
o Antipsychotics (Quetiapine, Clozapine for hallucinations; Pimavanserin - FDA approved for PD psychosis)
o Pipeline Agents (alpha-synuclein-targeting therapies, neuroprotective agents)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT)
o Physical & Occupational Therapy
o Lifestyle & Caregiver Support Programs
• Diagnostics & Digital Tools
o Biomarker-Based Tests (CSF, blood-based alpha-synuclein markers)
o AI-Powered Cognitive Assessments
o Imaging (MRI, PET)
By Platform:
• Small Molecules (rivastigmine, memantine)
• Biologics (monoclonals targeting alpha-synuclein, research stage)
• Digital Tools & Cognitive Platforms
By Technology:
• AI-Based Cognitive Testing
• Biomarker Discovery for Early PDD
• Digital Therapeutics
By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes
By Application:
• Early Cognitive Decline in PD
• Moderate-to-Severe PDD
• Clinical Research
Segmentation Summary:
Pharmacological treatments dominate today, but biologics, digital cognitive tools, and caregiver support programs are emerging as high-growth areas.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71917/parkinson-s-disease-related-dementia-market
Regional Analysis
North America
• ~44% share in 2024.
• Strong adoption of rivastigmine and Pimavanserin.
• FDA approvals and advanced dementia care infrastructure driving growth.
Europe
• ~29% share.
• Germany, UK, and France leading in integrated dementia and Parkinson's care.
• EMA pipeline reviews expanding drug access.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.4%.
• Rising PD prevalence in Japan, China, and India.
• Growing dementia awareness and diagnostic infrastructure.
Middle East & Africa
• Smaller market but increasing with aging demographics.
• Limited specialized dementia care facilities.
Latin America
• Brazil and Mexico driving regional adoption.
• Expanding memory care and neurology access.
Regional Summary:
North America and Europe dominate today's market, while Asia-Pacific grows fastest due to rising prevalence, healthcare investment, and expanding memory care infrastructure.
Market Dynamics
Key Growth Drivers:
• Rising global PD prevalence and aging populations.
• Increasing recognition and diagnosis of cognitive decline in PD.
• Pipeline therapies targeting alpha-synuclein and neuroprotection.
• Expanding digital diagnostics and caregiver support solutions.
Key Challenges:
• Lack of disease-modifying therapies.
• High caregiver and healthcare burden.
• Underdiagnosis of early cognitive decline.
• Limited infrastructure in low-income regions.
Latest Trends:
• Alpha-synuclein-targeting biologics under clinical trials.
• AI-driven neurocognitive testing for early detection.
• Digital caregiver support and remote monitoring solutions.
• Multimodal care models combining drugs, therapy, and digital health.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71917
Competitor Analysis
Major Players in the Market:
• Novartis AG (Rivastigmine - Exelon)
• Eisai Co., Ltd. (Donepezil - with Pfizer Inc.)
• ACADIA Pharmaceuticals Inc. (Pimavanserin - Nuplazid)
• Johnson & Johnson
• GlaxoSmithKline plc
• Eli Lilly and Company (neurodegenerative R&D pipeline)
• Biogen Inc.
• Roche Holding AG (biomarker research, pipeline therapies)
• AbbVie Inc.
• Cogstate Ltd. (digital cognitive assessment tools)
Competitive Summary:
Novartis leads with rivastigmine, while ACADIA dominates PD psychosis treatment with Pimavanserin. Eisai and Pfizer maintain donepezil presence, while Biogen, Roche, and Eli Lilly lead neurodegenerative R&D. Cogstate and other digital firms innovate in cognitive diagnostics. Competition centers on pipeline therapies, biomarker diagnostics, and digital health integration.
Conclusion
The Parkinson's Disease-Related Dementia (PDD) Market, valued at USD 4.3 billion in 2024, is projected to reach USD 7.9 billion by 2034, growing at a CAGR of 6.2%. Expanding diagnosis, symptomatic drug adoption, and biomarker-driven research will continue to shape the market.
Key Takeaways:
• Cholinesterase inhibitors remain standard, with Pimavanserin expanding use.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Biomarkers and AI-based diagnostics are transforming early detection.
• Multimodal care models integrating drugs, therapy, and digital health will define the future.
The next decade will transform PDD management from symptomatic-only approaches to precision-driven, biomarker-guided, and digitally integrated dementia care, creating strong opportunities for pharma, biotech, and digital health innovators.
This report is also available in the following languages : Japanese (パーキンソン病関連認知症市場), Korean (파킨슨병 관련 치매 시장), Chinese (帕金森病相关痴呆症市场), French (Marché de la démence liée à la maladie de Parkinson), German (Markt für Parkinson-bedingte Demenz), and Italian (Mercato della demenza correlata al morbo di Parkinson), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71917/parkinson-s-disease-related-dementia-market#request-a-sample
Our More Reports:
RNAi Drug Delivery Market
https://exactitudeconsultancy.com/reports/72371/rnai-drug-delivery-market
Epigenomics Market
https://exactitudeconsultancy.com/reports/72370/epigenomics-market
Astaxanthin Market
https://exactitudeconsultancy.com/reports/72369/astaxanthin-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease-Related Dementia (PDD) Market to Reach USD 7.9 Billion by 2034 here
News-ID: 4179643 • Views: …
More Releases from Exactitude Consultancy
Viral Vector Manufacturing Market to Surge to USD 43.04 Billion by 2034, Growing …
Introduction
The healthcare industry is entering a transformative era where precision therapies are reshaping how we treat diseases. Among the most groundbreaking innovations, viral vectors have emerged as critical enablers of gene and cell therapies. These engineered viruses act as vehicles to deliver therapeutic genetic material directly into patients' cells, making them indispensable for modern medicine. From treating rare genetic disorders to powering revolutionary CAR-T cell therapies in oncology, viral vectors…
Veterinary Vaccines Market to Reach USD 20.65 Billion by 2034, Growing at 6.4% C …
Introduction
Animal health is a cornerstone of global food security, sustainable agriculture, and public health. With rising concerns over zoonotic diseases, antimicrobial resistance, and livestock productivity, the role of veterinary vaccines has never been more critical. These vaccines not only protect animal populations from infectious diseases but also indirectly safeguard humans by preventing disease transmission from animals.
In 2024, the global Veterinary Vaccines Market is valued at USD 11.25 billion and is…
Intravenous Immunoglobulin (IVIG) Market to Reach USD 27.1 Billion by 2034, Grow …
Introduction
In recent years, the healthcare industry has seen significant progress in therapies targeting immune system disorders and rare diseases. At the forefront of these therapies is Intravenous Immunoglobulin (IVIG) - a plasma-derived product containing antibodies that play a crucial role in strengthening or modulating immune response. IVIG is widely used in treating primary and secondary immunodeficiency disorders, autoimmune diseases, neurological disorders, and hematological conditions.
With the rising prevalence of chronic illnesses,…
Lipid Nanoparticle Manufacturing Market to Reach USD 2.48 Billion by 2034, Growi …
Introduction
The pharmaceutical and biotechnology industries are undergoing a paradigm shift driven by the success of mRNA vaccines and the growing promise of gene therapies. At the heart of these breakthroughs are lipid nanoparticles (LNPs) - tiny, lipid-based carriers that safely deliver nucleic acids like mRNA, siRNA, and DNA into target cells. LNPs are now recognized as the gold standard for nucleic acid delivery, fueling advancements in infectious disease prevention, oncology,…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
